

REFERENCES

Chapter X

REFERENCES

- 1-Abdel Aziz T., Abdel Kader M.M., and Bahgat M.R. (1974): The effect of some long-acting steroidal contraceptives on lactation in rats. *Med. J. Cairo Univest.*, 24:287-292.
- 2-Abdel Kader M.M., Ibrahim A.A., Soliman L., Abo-Zahra H., Rizk A., Kawther S.M., and Abo-EL Naga H. (1984): Effects of medroxy-progesterone actate and adenosine triphosphate on fructolytic activity of human spermatozoa. *Egypt. J. Derm. Ven.*, 4:177-182.
- 3A Aedo A.R., Landgren B.M. and Diczfalusy E. (1981a): Studies on ovarian and adrenal steroids at different phases of the menstrual cycle. III: steroid and lutropin levels before and after administration of a single contractive dose of DMPA. *Contraception*, 24:117-135.
- 3B Aedo A.R., Landgren B.M., and Diczfalusy E. (1981b): Studies on ovarian and adrenal steroids at different phases of the menstrual cycle. IV: The effect of dexamethasone suppression and subsequent ACTH stimulation at different phases of the menstrual cycle and following the administration of 150 mg of depot-medroxyprogesterone actate. *Contraception*, 24:543-558.
- 4-Aggett P.J. and Harries J.T. (1979): Current status of zinc in health and disease states. *Arch. Dis. Child.*, 54:909-917.
- 5-Albrecht B.H., Schiff I., Tulchinsky D., and Ryan K., J. (1981): Objective evidence that placebo and oral medroxy progesterone acetate therapy diminish menopausal vasomotor flushes. *Am. J. Obstet. Gynecol.*, 139:631-635.
- 6-Amatayakul K. (1979a): The effects of Depo-provera on carbohydrate, lipids and vitamins metabolism. *J. Steroid. Biochem.*, 11:475-481.
- 7-Amatayakul K. (1979b): Safety and hazards of injectable hormonal contraceptives. *Singapore J. Obstet. Gynaecol.*, 9:57-77.
- 8-Amatayakul K., Sivasomboon B., and Thanagkul O. (1980): A study of the mechanism of weight gain in medroxyprogesterone acetate users. *Contraception*, 22:605-621.
- 9-Amatayakul K. Sivasomboon B. and Thanagkul O. (1978): Vitamin and trace

- mineral metabolism in Medroxyprogesterone acetate users. *Contraception*, 18:253-270.
- 10- Amatayakul K., and Suriyanon V. (1985): The effects of long-acting injectable contraceptives on carbohydrate metabolism. *Int. J. Gynaecol. Obstet.*, 23:361-368.
 - 11- Anderson D.G. (1972): The possible mechanisms of progestins on endometrial adenocarcinoma. *Am. J. Obstet. Gynecol.*, 113:195-211.
 - 12- Archer E. (1985): Injectable contraceptives, the role of long-acting progestogen in contraception in developing countries. *Save the children*. London, p.1-39.
 - 13- Arquilla E.R., Packer S.T. and Miyamoto S. (1978): Quoted by: Aggett P.J. and Harries J.T. (1979): Current status of zinc in health and disease states. *Arch. Dis. Child.*, 54:909-917.
 - 14- Astedt B., Jeppsson S., and Pandolfi M. (1972): Fibrinolytic activity of veins during use of depot medroxyprogesterone acetate as a contraceptive. *Fertil. Steril.*, 23:489-422.
 - 15- Austin J., and Staniford M. (1970): Oral contraceptives and copper metabolism. *Nature*, 225:81.
 - 16- Babcock J.C. et al. (1958): Quoted by Rinehart W., and Winter J. (1975): Injectable progestogens official debate but use increases. *Pop. Rep.*, ser., K., No 1,K-1.
 - 17- Badr F.N., Badr S., Ibrahim A., and Shaaban H.A. (1972): Chromosome studies on women using oral and injectable contraceptive drugs. *Med. J. Cairo Univest.*, 40:37-46.
 - 18- Bamji M.S., Safaya S., and Prema K. (1980): Low dose injectable contraceptive norethisterone enanthate 20 mg monthly-Metabolic side effects. *Contraception*, 23:23-36.
 - 19- Baumah P, K., Bates G., Ward A.M., and Skillen A.W. (1984): Maternal zinc status: a determination of central nervous system malformation. *Br. J. Obstet. Gynaecol.*, 91:788-790.
 - 20- Bearn A.G. (1980): Wilson's disease. In: *The Metabolic Basis of Inherited Disease*. 3rd edn. edited by. Stanbury, J.B., Wyngaarden, J.B., and

- Fredrickson, D.S., McGraw-Hill Book Company. New York., P.1033-1050.
- 21- Beauchamp P.J., Quigley M.M., and Held B. (1984): Evaluation of progestogen for postoperative adhesion prevention. *Fertil. Steril.*, 42:538-542.
 - 22- Beck P., Zimmerman E.D., and Eaton R.P. (1977): Effect of contraceptive steroids on arginine-stimulated glucagon and insulin secretion in women. III: Medroxyprogesterone acetate. *Metab.*, 26:1193-1198.
 - 23- Biesel W.R. (1976): Trace elements in infectious processes. *Med. Clin. Nor. Amer.*, 60: 831-847.
 - 24- Bloom H.J.G., (1971): Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer. *Br.J.Cancer*, 25: 250-265.
 - 25- Bloom H.J.G., and Hendry W.F. (1973): Possible role of hormones in treatment of metastatic testicular teratomas: tumor regression with medroxyprogesterone acetate. *Br. Med. J.*, 3:563-567.
 - 26- Boulard M., Blume K.G., and Beutler E. (1972): The effect of copper on red cell enzyme activities. *J. Clin. Invest.*, 51:459-461.
 - 27- Brakman P., Sobrero A.J., and Astrup T. (1970): Effects of different systemic contraceptives on blood fibrinolysis. *Am. J. Obstet. Gynecol.*, 106:187-192.
 - 28- Brenner P.F. (1982): The pharmacology of progestogens. *J. Reprod. Med.*, 27:490-495.
 - 29- Briggs M.H., Briggs M., and Austin J. (1971): Effects of steroid pharmaceuticals on plasma zinc. *Nature*, 232:480-481.
 - 30- Briggs M., and Briggs M. (1972): Plasma hormone concentrations in women receiving steroid contraceptives. *J. Obstet. Gynaecol. Brit. Comm.*, 79:946-950.
 - 31- Briggs M.H. (1978): Steroid contraception-metabolic and endocrine effects. In "Risks, Benefits, and Controversies in Fertility Control." edited by Sciarra J.J., Zatuchni G.I., and Speidel J.J., Harper and Row, Hagerstown, New York, London, P. 214-230.
 - 32- Bullock J.L., Massey F.M., and Gambrell R.D. (1975): Use of medroxyprogesterone acetate to prevent menopausal symptoms. *Obstet. Gynecol.*, 46:165-168.

- 33- Burch R.E., and Hahn K.J. (1979): Trace elements in human nutrition. Med. Clin. Nor. Amer., 63:1057-1088.
- 34- Burch R.E., and Sullivan J.F. (1976): Diagnosis of zinc, copper, and manganese abnormalities in man. Med. Clin. Nor. Amer., 60:655-660.
- 35- Burch R.E., and Sullivan J.F. (1976): Clinical and nutritional aspects of zinc deficiency and excess. Med. Clin. Nor. Amer., 60:675-685.
- 36- Burstein R., and Wasserman H.C. (1964): The effect of Provera on the fetus. Obstet. Gynecol., 23:931-934.
- 37- Buzina R., Jusic M., Sapunar J., and Milanovic N. (1980): Zinc nutrition and taste acuity in school children with impaired growth. Am. J. Clin. Nutr., 33:2262-2267.
- 38- Camakaris J., and Phillips M. (1983): Mutations in humans and animals which affect copper metabolism. J. Inher. Metab. Dis., 6 (suppl.):44-50.
- 39- Cantarow A., and Schepartz B. (1967): "Biochemistry". 4th ed., W.B. Saunders Company., Philadelphia and London., p. 643-647.
- 40- Carnes W.H. (1971): Role of copper in connective tissue metabolism. Fed. Proc., 30:995-1000.
- 41- Carruther M.E., Hobbs C.B., and Warren R.L. (1966): Raised serum copper and ceruloplasmin levels in subjects taking oral contraceptives. J. Clin. Path., 19:498-500.
- 42- Cartwright G.E., and Wintrobe M.M. (1964): Copper metabolism in normal subjects. Am. J. Clin. Nutr., 14:224-232.
- 43- Chesters J.K., and Will M. (1981): Zinc transport proteins in plasma. Br. J. Nutr., 46:111-118.
- 44- Chooi M.K., Todd J.K., and Boyd N.D. (1976): Influence of age and sex on plasma zinc levels in normal and diabetic individuals (Abst.). Nutr. Metab., 20:135-142.
- 45- Chvapil M. (1973): New aspect of the biological role of zinc-a stabilizer of macromolecules and biological membranes. Life Science, 13:1041-1049.
- 46- Chvapil M. (1979): Effect of zinc in cells and biomembranes. Med. Clin. Nor. Amer., 60:799-813.
- 47- Chvapil M., Weldy P.L., Clark D.S., and Zukoski C.F. (1975): Inhibitory

- effect of zinc ions on platelet aggregation and serotonin release reaction. *Life Science*, 16:561-571.
- 48- Clark I. (1968): Effects of magnesium ions on calcium and phosphorus metabolism. *Am. J. Physiol.*, 214:348-356.
- 49- Cornette J.C., Kirton K.T., and Duncan G.W. (1971): Measurement of medroxy progesterone acetate by radioimmunoassay. *J.Clin. Endocr.*, 33:459-466.
- 50- Cotzias G.C., Miller S.T., Papavasiliou P.S., and Tang I.C. (1976): Interactions between manganese and brain dopamine. *Med. Clin. Nor. Amer.*, 60:729-738.
- 51- Coutinho E.M., De Souza J.C., and Csapo A.I. (1966): Reversible sterility induced by Medroxyprogesterone injections. *Fertil. Steril.*, 17:261-266.
- 52- Crews M.G., Taper L.J., and Ritchey S.J. (1980): Effects of oral contraceptive agents on copper and zinc balance in young women. *Am. Clin. Nutr.*, 33:1940-1945.
- 53- Croxatto H.B., Diaz S., and Pavez M. (1983): Clinical chemistry in women treated with levonogestrel implants. *Contraception*, 27:281-288.
- 54- Csapo A., De Dousa-Filho M.B., De Souza J.C., and De Souza O. (1966): Effect of massive progestational hormone treatment on the parturient human uterus. *Fertil. Steril.*, 17:621-636.
- 55- Cuthbertson D.P., Fell G.S., Smith C.M., and Tilstone W.J. (1972): Metabolism after injury: effects of severity, nutrition, and environmental temperature on protein, potassium, zinc, and creatine. *Br. J. Surg.*, 59:925-931.
- 56- Dale E., and Simpson G. (1972): Serum magnesium levels of women taking an oral or long-term injectable progestational contraceptive. *Obstet. Gynecol.*, 39:115-119.
- 57- Daniel W. (1983): Biostatistics, In: "A Foundation For Analysis In The Health Science," 3rd edn., John Wiley and Sons, New York, p.185-210.
- 58- Daunter B., and Elstein M. (1973): Serum levels of copper, ceruloplasmin and ceruloplasmin oxidase activity in women using copper-containing intrauterine devices and in women taking combined oral contraceptives. *J. Obstet. Gynaecol. Brit. Comm.*, 80:644-647.

- 59- Davies I.J.T., Musa M., and Dormandy T.L. (1968): Measurement of plasma zinc. *J. Clin. Path.*, 21:359-365.
- 60- Dawson E.B., Frey M.J., Monistere N., and McGanity W.J. (1973): Essential metals in oral contraceptive tablets. *Am. J. Obstet. Gynecol.*, 116:412-414.
- 61- Deslypere J.P., Thiery M., and Vermeulen A. (1985): Effect of long-term hormonal contraception on plasma lipids. *Contraception*, 31:633-642.
- 62- Dhali K., Kumar M., Rastogi G.K., and Devi P.K. (1977): Short term effects of norethisterone oenanthate and medroxyprogesterone acetate on glucose, insulin, growth hormone and lipids. *Fertil. Steril.*, 28:156-158.
- 63- Diczfalussy E. (1986): New developments in oral, injectable and implantable contraceptives, vaginal rings and intrauterine devices. *Contraception*, 33:7-30.
- 64- Dokumov S.I. (1968): Serum copper and pregnancy. *Am. J. Obstet. Gynecol.*, 101:217-222.
- 65- Donde U.M., and Virkar K. (1976): Effect of oral (Combination of and progestogen alone) and injectable contraceptives on serum copper levels. *Indian J. Med. Res.*, 64:787-791.
- 66- Doody E., and Bain J. (1985): The effect of oral medroxyprogesterone acetate and methyl testosterone on sexual functioning in a male contraceptive trial. *Contraception*, 31:65-70.
- 67- Dugdale M., and Masi A.T. (1971): Hormonal contraception and thromboembolic disease: effects of the oral contraceptives on hemostatic mechanisms. *J. Chron. Dis.*, 23:775-790.
- 68- Durlach J. (1967): Magnesium deficiency thrombosis. *Lancet*, 1:1382.
- 69- Edgren R.A., Jones R.C., and Peterson D.L. (1967): A biological classification of progestational agents. *Fertil. Steril.*, 18:238-256.
- 70- Editorial (1980): Oral contraceptives-mechanisms in thromboembolism. *Lancet*, 1:1118-1119.
- 71- Egyptian Fertility Care Society "EFCS" (1983): WHO injectables project. Minutes, Meeting held on 1983, Cairo.
- 72- Eisa E.A., Al-Gauhari A., Al-Nagdy S.A., and Yanni N. (1972): Blood zinc

- and copper in normal and in diseased Egyptians. *J. Trop. Med. Hyg.*, 75:246-250.
- 73- El-Habashy M.A., Mishell D.R. and Moyer D.L. (1970): Effect of supplementary oral estrogen on long acting injectable progestogen contraception. *Obstet. Gynecol.*, 35:51-54.
- 74- Elder M.G. (1984): Injectable contraception. *Clin. Obstet. Gynaecol.*, 11:723-740.
- 75- El-Mahgoub S., Karim M., Ammar R., and Ghareeb A. (1972): The effects of injectable contraceptives on the thyroid functions. In: "Studies on IUDs and Injectables in Arab Republic of Egypt (A.R.E.)" edited by: Osman, E. Scientific Book Centre, Cairo, P. 51.
- 76- El-Mahgoub S., Karim M., Ammar R., and Sayed A. (1972): Long-term use of DMPA as a contraceptive. *Acta Obstet. Gynaecol. Scand.*, 51:251-255.
- 77- Evans G.W. (1976): Trace elements in human health and disease (Prasad, A.S. ed.) Academic Press. New York. P. 181-210.
- 78- Evans G.W., Grace C.I., and Hahn C. (1973): Homeostatic regulation of zinc absorption in the rat. *Proc. Soc. Exp. Biol. Med.*, 143:723-725.
- 79- Evans G.W., and Wiederanders R.E. (1967): Blood copper variation among species. *Am. J. Physiol.*, 213:1183-1185.
- 80- Evans G.W., and Wiederanders R.E. (1968): Effect of hormones on ceruloplasmin and copper concentrations in the plasma of the rat. *Am. J. Physiol.*, 214:1152-1154.
- 81- Family Health Review (1985): Injectables. Published by Family of the Future, Cairo, no. 9.
- 82- Farrell E.C. (1984): Minerals. In: "Clinical Chemistry, Theory, Analysis and Correlation." edited by Kaplan L.A., and Pesce A.J.P. The C.V. Mosby Company. ST. Louis P. 1065-1080.
- 83- Favier A., Ruffieux D., Decoux G., and Arnaud J. (1983): Results of a study to detect the effects on neonates of copper and zinc deficiency during pregnancy. *J. Inher. Metab. Dis.*, 6 (Suppl.) :93-94.
- 84- Fertility Care (1985): Facts about injectable contraceptives. No 28-29, p. 1-10.

- 85- Flink E.B. (1976): Quoted by Prasad A.S. (1978) In: "Trace Elements and Iron in Human Metabolism." Plenum Medical Book Company, New York, p. 159-210.
- 86- Flink E.B., Stutzman F.L., Anderson A.R., Konig T., and Fraser R. (1954): Magnesium deficiency after prolonged parenteral fluid administration and after chronic alcoholism complicated by delirium tremens. J. Lab. Clin. Med., 43:169-183.
- 87- Flynn A., Paries W.J., Strain W.H., Hill O.A., and Fratianna R.B. (1971): Rapid serum zinc depletion associated with corticosteroid therapy. Lancet, 2:1169.
- 88- Foley B., Johnson S.A., Hackley B., Smith J.C., and Halsted J.A. (1968): Zinc content of human platelets. Proc. Soc. Exp. Biol. Med., 123:265-269.
- 89- Fotherby K., and Koetsawang S. (1982): Metabolism of injectable formulations of contraceptive steroids in obese and thin women. Contraception, 26:51-58.
- 90- Fotherby K., Koestswang S., and Mathrubutham M. (1980): Pharmacokinetic study of different doses of Depo-Provera. Contraception, 22:527-536.
- 91- Fotherby K., Saxena B.N., Shrimanker K., Hingorani V., Takker D., Diczfalussy E., and Landgren B.M. (1980): A preliminary pharmacokinetic and pharmacodynamic evaluation of depo medroxyprogesterone acetate and norethisterone enanthate. Fertil. Steril., 34:131-139.
- 92- Fotherby K., Shrimanker K., and Saxena B.N. (1978): Assay of long acting contraceptive steroid formulations in rabbits. Contraception, 17:365-373.
- 93- Fraser I.S., and Diczfalussy E. (1983): Steroidal contraception and abnormal bleeding. In: "Long-Acting Contraception." edited by Goldsmith, A., and Topozada, M., Production: Ruvenia Thomas, PARER, Northwestern University., P. 76-92.
- 94- Fraser I.S., and Weisberg E. (1981): A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med. J. Aust. (Suppl.) :1-20.
- 95- Fraser I.S., and Weisberg E. (1982): Fertility following discontinuation of different methods of fertility control. Contraception, 26:389-405.

- 96- Frieden E., and Osaki S. (1969): Serum copper and oral estrogen. Science, 163:959.
- 97- Funckes C.G., Chvapil M., Carrol R.W., and Bressler R. (1976): Effect of long-acting contraceptive drug, norethisterone enanthate on serum zinc and copper in human volunteers. Contraception, 14:291-295.
- 98- Gambrell R.D. (1982): Clinical use of progestins in the menopausal patient, dosage and duration. J. Reprod. Med., 27:351-538.
- 99- Gambrell R.D., Massey F.M., and Casteneda T.A. (1979): Quoted by Brenner P.F. (1982): The pharmacology of progestogens. J. Reprod. Med., 27:490-495.
- 100- Gambrell R.D., Massey F.M., Casteneda T.A., Ugenas R.J., Ricci C.A., and Wright J.M. (1980): Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet. Gynecol., 55:732-737.
- 101- Gardner J.M., and Mishell D.R. (1970): Analysis of bleeding patterns and resumption of fertility following discontinuation of a long acting injectable contraceptive. Fertil. Steril., 21:286-290.
- 102- Gerretsen G., Kremer J., Bleumink E., and Nater J.P. (1975): Dinitrochlorobenzene sensitisation test in women on hormonal contraceptives. Lancet, 1:347-349.
- 103- Gerretsen G., Kremer J., Nater J.P., Bleumink E., and De Gast G.C. (1979): Immune reactivity of women on hormonal contraceptives. Contraception, 19:83-89.
- 104- Ghali A.A., Youssef A.F., Abul-Fadl M.A.M., and Fayad M.M. (1973): Evaluation of function of pituitary-adrenal axis in patients on oral and long-acting gestagens. J. Kuwait Med. Assoc., 7:135-153.
- 105- Ghosh A., Fong L.Y.Y., Wan C.W., Liang S.T., Woo J.S.K., and Wong V. (1985): Zinc deficiency is not a cause for abortion, congenital abnormality and small for gestational age infants in Chinese women. Br. J. Obstet. Gynaecol., 92:886-891.
- 106- Goldenstein A. (1982): Depo-Provera contraceptive injections in quarterly administration during breast feeding period. From reproduction health care, international symposium, U.S.A, 1982. Contracept. Deliv. Syst., 3 (Suppl.).

- 107- Goldsmith N.F., and Baumberger J.P. (1967): Mineral changes after norethynodrel. *Lancet*, 2:567-568.
- 108- Greaves M.W. (1972): Quoted by Hallbook, T., and Hedelin, H. (1977): Zinc metabolism and surgical trauma. *Br. J. Surg.*, 64:271-280.
- 109- Greaves M.W., Woyde T.R.C. (1968): Plasma-zinc in psoriasis. *Lancet*, 2:278.
- 110- Guder W.G., and Einfluss V.P. (1979): Quoted by Richterich R., and Colombo J.P. (1981), In: "Clinical Chemistry, Theory, Practice, and Interpretation." John Wiley and Sons. New York, P.97-130.
- 111- Guilloff E., Ibarra-Polo A., Zanartu J., and Mischer T.W. (1974): Effect of contraception on lactation. *Am. J. Obstet. Gynecol.*, 118:42-45.
- 112- Gupta C., Osterman J., Santen R., and Wayne C. (1979): In-vivo metabolism of progestins. *J. Clin. Endocrinol. Metab.*, 48:816-820.
- 113- Guyton A.G. (1981): "Textbook of Medical Physiology". 6th ed., W.B. Saunders company, Philadelphia, London. Toronto., p. 4, 22, 52, 104, 107, 113, 1052.
- 114- Habib F.K. (1978): Quoted by Aggett P.J., and Harries J.T. (1979): Current status of zinc in health and disease states. *Arch. Dis. Child.*, 54:909-917.
- 115- Hall P.E. (1983): The injectable contraceptive debate: an update. In: "Long-Acting Contraception". edited by Goldsmith A., and Topozada M., Production: Ruvenia Thomas, PARER, Northwestern University., p. 109-115.
- 116- Hallbook T., and Hedelin H. (1977): Zinc metabolism and surgical trauma. *Br. J. Surg.*, 64:271-273.
- 117- Halsted J.A. (1969): Plasma zinc and copper levels. *Am. J. Obstet. Gynecol.*, 103:465-466.
- 118- Halsted J.A., Hackley B.M., and Smith J.C. (1968): Plasma-zinc and copper in pregnancy and after oral contraceptive. *Lancet*, 2:278-279.
- 119- Halsted J.A., and Smith J.C. (1970): Plasma zinc in health and disease. *Lancet*, 1:322-324.
- 120- Halsted J.A., Smith J.C., and Irwin M.I. (1974): A conspectus of research on zinc requirements of man. *J. Nutr.*, 104:345-378.

- 121- Hanze S., and Seyberth H. (1967): Quoted by Prasad A.S. (1978), In: "Trace Elements and Iron in Human Metabolism.", Plenum Medical Book Company., New York., P. 159-210.
- 122- Haratake J., Horie A., Nakashima A., Takeda S., and Mori A. (1986): Minute hepatoma with excessive copper accumulation. Arch. Pathol. Lab. Med., 110:192-194.
- 123- Harlap S., and Elder J. (1980): Births following oral contraceptive failure. Obstet.Gynecol., 55:447-452.
- 124- Harper H.A., Rodwell V.W., and Mayes P.A. (1977): "Review of Physiological Chemistry", 16th ed, Lange Medical Publications. Los Altos, California, P.521-556.
- 125- Hartoma T.R., Nahoul K., and Netter A. (1977): Quoted by Agett P.J., and Harries J.T. (1979): Current status of zinc in health and disease. Arch. Dis. Child., 54:909-950.
- 126- Hefnawi F., El- Sheikha Z., Hasseeb F., Abdin F., and Abdel Wahed H. (1972): IN: "Studies on IUDs and Injectables in Arab Republic of Egypt", edited by Osman, E., Scientific Book Center, Cairo, P. 50.
- 127- Hellman L., Koichiro Y., Zumoff B., Levin Y., Kream J., and Fukushima D. (1979): The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J. Clin. Endocrinol. Metab., 42:912-917.
- 128- Henkin R.I., Schechter P.J., Hoyer R., and Mattern C.F.T. (1971): In a conspectus of research on zinc requirements of man. By Halsted, J. (1974). J. Nutr., 104:345-350.
- 129- Henry R.J., Cannon D.C., and Winkelman J.W. (1974): "Clinical Chemistry, Principles and Technics". 2nd ed., Harper and Row Publishers, Hagerstown, p. 657-690.
- 130- Hiraoka M., Yamacishi S., and Sano T. (1968): Role of calcium ions in the contraction of vascular smooth muscle. Am. J. Physiol., 214:1084-1089.
- 131- Holtz G., Neff M., Mathur S., and Perry L.C. (1983): Effect of medroxy progesterone acetate on peritoneal adhesion formation. Fertil. Steril., 40:542-544.
- 132- Hulka J.F., Mohr K., and Lieberman M.W. (1965): Effect of synthetic

- progestational agents on allograft rejection and circulating antibody production. *Endocrinol.*, 77:897-901.
- 133- Hurley L.S. (1976): Trace elements and teratogenesis. *Med. Clin. Nor. Amer.*, 60:771-777.
- 134- Hurley L.S. (1981): Teratogenic aspects of manganese, zinc and copper nutrition. *Physiol. Rev.*, 61:249-295.
- 135- Ibrahim A., Fayad M., Abul Fadl M., El Tomy A., Kadry S., and Khallafallah A. (1966): Experience in conception control with a parenteral long-acting progestogen-estrogen combination. In: "Studies on IUDs and Injectables in Arab Republic of Egypt", edited by Osman, E. (1972), Scientific Book Center, Cairo, P:42.
- 136- Information from the Swedish Health Authorities (1983): Depo-Provera. *Brit. J. Fam. Plann.*, 8:123-135.
- 137- Innes C. (1985): Affective illness and zinc deficiency. *Lancet*, 1:645-646.
- 138- International Planned Parenthood Federation "I.P.P.F." (1983): DMPA-Scientific Issues.
- 139- International Planned Parenthood Federation "I.P.P.F." (1982): Statement on injectable contraception.
- 140- International Planned Parenthood Federation "I.P.P.F." (1982): Injectable contraceptives-safe and effective.
- 141- Jeppsson S. (1972): Experience with DMPA (Depo-Provera) as a contraceptive agent. *Acta Obstet. Gynaecol. Scand.*, 51:257-263.
- 142- Jeppsson S., Gershagen S., Johanson E.D.B., and Rannevik G. (1982): Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins, and prolactin in women during long term use of Depo-Provera as a contraceptive agent. *Act. Endocrinol.*, 99:339-343.
- 143- Jeppsson S., and Johansson E.D.B. (1976): Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of Depo-Provera to women. *Contraception*, 14:461-467.
- 144- Johnson N.C., Kheim T., and Kountz W.B. (1959): Influence of sex hor-

- mones on total serum copper. *Proc. Soc. Exp. Biol. Med.*, 102:98-99.
- 145- Junkmann K. (1954): Quoted by Rinehart W., and Winter J. (1975): Injectable progestogens-Official debate but use increases. *Pop. Rep.*, ser. K, No.1, K-1.
- 146- Junkmann K., and Witzel H. (1958): Quoted by Rinehart W., and Winter J. (1975): Injectable progestogens-Official debate but use increases. *Pop. Rep.*, Ser. K, No. 1, k-1.
- 147- Kamal I., Hefnawi F., and Younis N. (1969): Post cessation fertility and menstrual pattern after the use of a long acting injectable progestogen-estrogen combination. In: "Studies on IUDs and Injectables in Arab Republic of Egypt". edited by Osman, E. (1972), Scientific Book Centre, Cairo, P. 52.
- 148- Kamal I., Hefnawi F., Younis N., Moheildin O., and El-Ashmawy S. (1969): Liver function studies with an estrogen-progestogen injectable contraceptive, In: "Studies on IUDs and Injectables in Arab Republic of Egypt", edited by Osman, E. (1972), Scientific Book Center, Cairo, p. 53.
- 149- Kamal I., Hefnawi F., Younis N., Wassef S.A., Kandil O. and Abdalla M. (1968): Experience with long-acting injectable progestogen-estrogen combination in fertility control. In: "Studies on IUDs and Injectables in Arab Republic of Egypt", edited by Osman, E. (1972), Scientific Book Center Cairo, P.43.
- 150- Kaplan L.A., and Pesce A.J. (1984): Atomic absorption. In: "Clinical Chemistry, Theory, Analysis and Correlation, "The C.V. Mosby Company, ST. Louis, P.62-1005.
- 151- Karim M., Ammar R., El-Mahgoub S., EL-Ganzoury B., Fikri F., and Abdou, I. (1971): Injectable progestogen and lactation. *Brit. Med. J.*, 23:200-203.
- 152- Karim M., Ammar A., Badawi S., Ganzoury B., and Iskandar S. (1969): One year trial with an injectable contraceptive (Deladroxate). In: "Studies on IUDs and Injectables in Arab Republic of Egypt". edited by Osman, E. (1972), Scientific Book Center, Cairo, P.44.
- 153- Karim M., and EL-Mahgoub S. (1970): Injectable steroids as a method of

- contraception. *Ain Shams. Med. J.*, 21:543-550.
- 154- Karim M., Yassin S., Ammar R., EL-Mahgoub S., EL-Ganzoury B., and Fikri F. (1971): Effects of injectable contraceptive progestogen on the puerperal uterus. In: "Studies on IUDs and Injectables in Arab Republic of Egypt". edited by Osman, E. (1972), Scientific Book Center, Cairo, P.45.
 - 155- Kato J., Onouchi T., and Okinaga S. (1978): Hypothalamic and hypophysial progesterone receptors: estrogen-priming effect, differential localization, 5-alpha-dihydroprogesterone binding and nuclear receptors. *J. Steroid. Biochem.*, 9:419-427.
 - 156- Katz Z., Lancet M., Skornik J., Chemke J., and Klinberg M. (1985): Teratogenicity of progestogens given during the first trimester of pregnancy. *Obstet. Gynecol.*, 65:775-780.
 - 157- Keating F.R., Jones J.D., EL-Verack A.R., and Randall R.V. (1969): The relation of age and sex to distribution of values in healthy adults of serum calcium, inorganic phosphorus, magnesium, alkaline phosphatase, total proteins, albumin, and blood urea, *J. Lab. Clin. Med.*, 73:825-834.
 - 158- Keillin D., and Mann J. (1940): Quoted by Riordan J. F. (1976): *Biochemistry of zinc. Med. Clin. Nor. Amer.*, 60:661-674.
 - 159- King T.M., Burkman R.T., and Atienza M.F. (1978): Other dosage forms and routes, injectables MPA. In: "Risks, Benefits, and Controversies in Fertility Control". edited by Sciarra J.J., Zatuchni G.I., and Speidel J.J., Happer and Raw, New York, P.257.
 - 160- Klevay L.M., Reck S., and Barcome D.F. (1979): Evidence of dietary copper and zinc deficiencies. *JAMA*, 241:1916-1918.
 - 161- Koetsawang S., Shrimanker K., and Fotherby K. (1979): Blood levels of medroxyprogesterone acetate after multiple injections of Depo-Provera or Cycloprovera. *Contraception*, 20:1-27.
 - 162- Kopelman P.G., Pilkington T.R.E., White N., and Jeffcoate S.L. (1980): Abnormal sex steroid secretion and binding in massively obese women. *Clin. Endocrinol.*, 12:363-369.
 - 163- Laker M. (1982): On determining trace element levels in man: the uses of blood and hair. *Lancet*, 1:260-262.

- diets. *Am. J. Clin. Nutr.*, 40:1368-1379.
- 165- Laksmanan F.L., Rao R.B., Kim W.W., and Kelsay J.L. (1984): Magnesium intakes, balances and blood levels of adults consuming self-selected diets. *Am. J. Clin Nutr.*, 40:1380-1389.
- 166- Lan P.T., Aedo A.R., Landgren B.M., Johannisson E., and Diczfalussy E. (1984): Return of ovulation following a single injection of Depo Medroxyprogesterone Acetate: a pharmacokinetic and pharmacodynamic study. *Contraception*, 29:1-18.
- 167- Lane G., Siddle N.C., Ryder T.A., Pryse-Davies J., King R.J.B., and Whitehead M.I. (1980): Is provera the ideal progestogen for addition to post menopausal estrogen therapy? *Fertil.Steril.*, 45:345-352.
- 168- Larsson B., Ljung B., and Hamberger L. (1976): The influence of copper on the in-vitro motility of the human Fallopian tube. *Am. J. Obstet. Gynecol.*, 125:682-690.
- 169- Laudanski T., Kobylec E., and Akerlund M. (1981): Influence of copper ions on uterine activity. *Contraception*, 24:195-202.
- 170- Leach R.M. (1976): Quoted by Prasad A.S. (1978): "Trace Elements and Iron in Human Metabolism". Plenum Medical Book Company, New York and London, p. 191-230.
- 171- Leiman G. (1972): Depo medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure. *Am. J. Obstet. Gynecol.*, 114:97-102.
- 172- Li T.K. and Vallee B.L. (1973): The biochemical and nutritional role of trace elements. In: "Modern Nutrition in Health and Disease Dietotherapy". edited by Goodhart R.S., and Shils M.E., 5th ed. Lea and Febiger, Philadelphia, p. 372-399.
- 173- Liew D.F.M., Charles S.A., and Yong Y.M. (1985): Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. *Contraception*, 31:51-64.
- 174- Liska S.K., Kerkay J., and Pearson K.H. (1985): Determination of copper in whole blood, plasma and serum using Zeeman effect atomic absorption spectroscopy. *Clin. Chim. Acta*, 150:11-19.

- in whole blood, plasma and serum using Zeeman effect atomic absorption spectroscopy. Clin. Chim. Acta, 150:11-19.
- 175- Liskin L.S., and Quillin W.F. (1983): Long-acting progestins-Promise and prospects. Pop. Rep., ser. K., No 2, k-18-55.
 - 176- Lobo R.A., and Gibbons W.E. (1982): The role of progestin therapy in breast disease and central nervous system function. J. Reprod. Med., 27:515-519.
 - 177- Luciano A.A., Tuksoy R.N., and Carleo J.L. (1985): Clinical and endocrine evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis (Abst.). The forty-first annual meeting of the American Fertility Society. Published by the American Fertility Society. Alabama, p.127.
 - 178- Luukkainen T., Lahteenmaki P., and Lahteenmaki P. (1983): Bleeding patterns with long-acting steroidal contraceptives. In: "Long-acting Contraception". edited by Goldsmith A., and Topozada M., Ruvenia Thomas, PARER., Northwestern University, p. 69-75.
 - 179- Macleod J. (1975): Minerals. In: "Davidson's Principles and Practice of Medicine". 11th ed., Churchill Livingstone. Edinburgh. London. New York., p.126-654.
 - 180- Maddox I.S. (1973): The role of copper in prostaglandin synthesis. Biochem. Biophys. Acta, 306:74-81.
 - 181- Malkasian C.D., Decker D.G., Mussey E. and Johnson C.E. (1971): Progestogen treatment of recurrent endometrial carcinoma. Am. J. Obstet. Gynecol., 110:15-23.
 - 182- Mandel F.P., Davidson B.J., Erlik Y., and Judd H.L. (1982): Effects of progestins on bone metabolism in postmenopausal women. J. Reprod. Med., 27:511-514.
 - 183- Maqueo M. (1980): Quoted by Fraser I.S., and Weisberg E. (1981): A Comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med. J. Aust., 1 (suppl.).
 - 184- Margen S., and King J.C. (1975): Effects of oral contraceptive agents on the metabolism of some trace minerals. Am. J. Clin. Nutr., 28:392-402.

- 185- Marocchi G.C.A., Silverio F.D., and Conti C. (1979): Progestational therapy in human renal carcinoma and steroid receptors. *J. Steroid Biochem.*, 7:923-927.
- 186- Martin C.R. (1976): "Textbook of Endocrine Physiology". Williams and Wilkins Company, Baltimore, p.155-188.
- 187- Mason W.B. (1974): Flame photometry. In: "Clinical Chemistry", 2nd ed., edited by: Heryy R.J., Cannon D., and Winkelman, J.W., Medical Department, Harper and Row, Hagerstown, p.49-710.
- 188- Maurer J.H., and Bonaventura L.M. (1983): The effect of aqueous progesterone on postoperative adhesion formation. *Fertil. Steril.*, 39:485-489.
- 189- Mc Bean L., and Halsted J.A. (1969): Fasting versus postprandial plasma zinc levels. *J. Clin. Path.*, 23:623.
- 190- Mc Call J.T., Goldstein N.P., and Smith L.H. (1971): Implication of trace metals in human diseases. *Fed. Proc.*, 30:1011-1015.
- 191- Mc Donough P.G. (1985): Progesterone therapy: benefit versus risk. *Fertil. Steril.*, 44:13-16.
- 192- Meade T.W. (1982): Effects of progestogen on the cardiovascular system. *Am. J. Obstet. Gynecol.*, 142:776-780.
- 193- Meade T.W., Greenberg G., and Thompson S.G. (1980): Progestogen and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50 and 30 µg oestrogen preparations. *Br. Med. J.*, 49:1157-1161.
- 194- Meadows N.J., Smith M.F., Keeling W.N., Ruse W., Day J., Scopes J.W., Thompson R.H., and Bloxam D.L. (1981): Zinc and small babies. *Lancet*, 2:1135-1136.
- 195- Melis G.B., Strigini F., Fruzzetti F., Paoletti A.M., Rainer E., Dusterberg B., and Fioretti P. (1981): Norethisterone Enanthate as an injectable contraceptive in puerperal and non-puerperal women. *Contraception*, 23:77-88.
- 196- Melo J.F., and Coutinho E.M. (1977): Inhibition of spermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthate. *Contraception*, 15:627-633.

- 197- Mertz W, (1981): The essential trace elements. Science, 213:1332-1338.
- 198- Minkin S. (1980): Depo-Provera. A critical analysis. Women and Health, 5:49-60.
- 199- Mishell D.R., EL-Habashy M., Good R.G., and Moyer D.L. (1967): Study of long-acting injectable medroxyprogesterone acetate for contraceptive use. In: "Studies on IUIDs and Injectables in Arab Republic of Egypt", edited by Osman, E. (1972), Scientific Book Center., Cairo, p.46.
- 200- Mishell D.R., EL-Habashy M.A., Good R.G., and Moyer D.L. (1968): Contraception with an injectable progestin. Am. J. Obstet. Gynecol., 101:1046-1053.
- 201- Mishell D.R., Kharma K.M., Thornecycorft I.H., and Nakamura R.M. (1972): Estrogenic activity in women receiving an injectable progestogen for contraception. Am. J. Obstet. Gynecol., 113:372-376.
- 202- Molinis (1970): Quoted by Upjohn Company (1980): Commentary on Depo Provera. p.12-17.
- 203- Morrison J.C., Martin D.C., Blair R.A., Anderson G.D., Bates G.W., Rivlin M.E., Propst M.G., and Needham R. (1980): The use of medroxy progesterone acetate for relief of climacteric symptoms. Am. J. Obstet. Gynecol., 138:99-104.
- 204- Muggia F.M., Cassileth P., Ochoa M., Flatow F.A., and Hyman G.A. (1968): Treatment of breast cancer with medroxyprogesterone acetate. Ann. Int. Med., 68:328-337.
- 205- Mukherjea M. (1981): Depo-Provera: Clinical evaluation. Contracept. Deliv. Syst., 5:259-268.
- 206- Nagpoul J.P., Singh R., Amm M.K., and Majumdar S. (1984): Effect of medroxyprogensterone acetate on the intestinal absorptive functions in protein-deficient-rat. Biochem. Int., 8:739-748.
- 207- O'Dell B.L. (1976): Biochemistry of copper. Med. Clin. Nor. Amer., 60:687-703.
- 208- O'Dell B.L. (1976): Biochemistry and physiology of copper in vertebrates. In: "Trace Elements in Human Health and Disease". Vol. 1., edited by Prasad, A.S. Academic Press, New York, p. 391-413.

- 209- O'Dell B.L., Hardwick B.C., Reynolds G., and Savage J.E. (1961): Connective tissue defects in the chick resulting from copper deficiency. *Proc. Soc. Exper. Bio. Med.*, 108:402-405.
- 210- O'Leary J.A., and Spellacy W.N. (1968): Serum copper alteration after ingestion of an oral contraceptive. *Science*, 162:182.
- 211- O'Leary J.A., and Spellacy W.N. (1969): Zinc and copper levels in pregnant women and those taking oral contraceptives. *Am. J. Obstet. Gynecol.*, 103:131-132.
- 212- Omran A.R. (1983): Contraception in the Arab world. In: "Long-Acting Contraception", edited by Goldsmith A., and Topozada M., Ruvenia Thomas, PARER, Northwestern University. p.1-7.
- 213- Orten J.M., and Neuhaus O.W. (1975): "Human Biochemistry", 9th ed. The C.V. Mosby Company. Saint Louis, p. 507-560.
- 214- Ortiz A., Hiroi M., Stanczky F.Z., Goebelsmann U., and Mishell D.R. (1977): Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of Depo-MPA. *J. Clin. Endocrinol. Metab.*, 44:32-38.
- 215- Osman E.H. (1986): Phase IV - multicentric study with NET-EN and DMPA injectable contraceptives in Egypt, 13th annual meeting, Egyptian Fertility Care Society, Cairo, 1986. (Personal contact).
- 216- Ottosson U.B., Nilsson B., Sodergard R., and Schoultz B.V. (1985): Effects of progesterone, progestogens and danazol on the specific cortisol binding in human plasma. *Fertil. Steril.*, 43:856-860.
- 217- Paine C.H., Wright F.W., and Ellis F. (1970): The use of progestogen in the treatment of metastatic carcinoma of the kidney and uterine body. *Br. J. Cancer.*, 24:277-281.
- 218- Pardthaisong T., Gray R.h., and Mc Daniel E.B. (1980): Return of fertility after discontinuation of DMPA and intrauterine devices in Northern Thailand. *Lancet*, 1:509-511.
- 219- Patterson K.Y., Holbrook J.T., Bodner J.E., Kelsay J.L., Smith J.J.C., and Veillon C. (1984): Zinc, copper, and manganese intake and balance for adults consuming self-selected diets. *Am. J. Clin. Nutr.*, 40:1397-1403.

- 220- Pekarek R.S., Beisel W.R., Bartelloni P.J., and Bostian K.A. (1972): Determination of serum zinc concentrations in normal adult subjects by Atomic absorption spectrophotometry. *Am. J. Clin. Path.*, 57:506-510.
- 221- Perez-Palacios G., Fernandez-Aparicio M.H., Medina M., Zacarias J., and Ulloa-Aguirre A. (1981): On the mechanism of action of progestins. *Acta Endocrinol.*, 97:320-328.
- 222- Piver M.S., Barlow J.J., Lurain J.R., and Blumenson L.E. (1980): Medroxy progesterone Acetate Vs. Hydroxyprogesterone Caproate (Delalutin) in women with metastatic endometrial carcinoma. *Cancer*, 45:268-272.
- 223- Podratz K.C., O'Brien P.C., Malkasian G.D., Decker D.G., Jefferies J.A., and Edmonson J.H. (1985): Effects of progestational agents in treatment of endometrial carcinoma. *Obstet. Gynecol.*, 66:106-110.
- 224- Prasad A.S. (1967): Nutritional metabolic role of zinc. *Fed. Proc.*, 26:172-184.
- 225- Prasad A.S. (1976): "Trace Elements in Human Health and Disease". Academic Press, New York., P.1-310.
- 226- Prasad A.S. (1978): Magnesium-Manganese. In: "Trace Elements and Iron in Human Metabolism", Plenum Medical Book Company, New York. p.159-201.
- 227- Prasad A.S., and Oberleas D. (1971): Changes in activities of zinc-dependent enzymes in zinc deficient tissues of rats. *J. Appl. Physiol.*, 31:842-846.
- 228- Prasad A.S., and Oberleas D. (1973): Quoted by Aggett PJ., and Harries J.T. (1979): Current status of zinc in health and disease states. *Arch. Dis. Child.*, 54:909.
- 229- Prasad A.S., Oberleas D., Lei K.Y., Moghissi K.S., and Stryker J.C. (1975): Effect of oral contraceptive agents on nutrients: minerals. *Am. J. Clin. Nutr.*, 25:377-384.
- 230- Prema K., Ramalakshmi B.A., and Babu S. (1980): Serum copper and zinc in hormonal contraceptive users. *Fertil. Steril.*, 33:267-271.
- 231- Ragan H.A., Nacht S., Lee G.R., Bishop C.R., and Cartwright G.E. (1969): Effect of ceruloplasmin on plasma iron in copper-deficient swine. *Am. J. Physiol.*, 217:1320-1323.

- 232- Resseguie L.J., Hick J.F., Bruen J.A., Noller K.L., O'Fallon W.M., and Kurland L.T. (1985): Congenital malformation among offspring exposed in-utero to progestins. *Fertil. Steril.*, 43:514-519.
- 233- Richterich R., and Colombo J.P. (1981): "Clinical Chemistry. Theory, Practice, and Interpretation". John Wiley and Sons. New York, p.94-109.
- 234- Rinehart W., and Winter J. (1975): Injectable progestogens-official debate but use increases. *Pop. Rep., Ser. K., No. 1*, k-1-16.
- 235- Riordan J.F. (1976): Biochemistry of zinc. *Med. Clin. Nor. Amer.*, 60:661-674.
- 236- Riordan J.F., and Vallee B.V. (1976): Quoted by Aggett P.J., and Harries J.T. (1979): Current status of zinc in health and disease states. *Arch. Dis. Child.*, 54:909-917.
- 237- Roberts D.K., Horbelt D.V., and Powell L.C. (1975): The ultrastructure response of human endometrium to medroxyprogesterone acetate. *Am. J. Obstet. Gynecol.*, 123:811-818.
- 238- Rogers J.M., Keen C.L., and Hurley L.S. (1985): Zinc deficiency in pregnant long-evans hooded rats: teratogenicity and tissue trace elements. *Teratology*, 31:89-100.
- 239- Rozier J.C., and Underwood P.B. (1974): Use of progestational agents in endometrial adenocarcinoma. *Obstet. Gynecol.*, 44:60-64.
- 240- Rubinfeld Y., Maor Y., Simon D., and Modai D. (1979): A progressive rise in serum copper levels in women taking oral contraceptives. *Fertil. Steril.*, 32:599-601.
- 241- Russ E.M., and Raymunt J. (1956): Influence of oestrogens on total serum copper and ceruloplasmin. *Proc. Soc. Exp. Bio. Med.*, 92:465-466.
- 242- Sabry A., Fathalla M., Shaaban M., and Morad M. (1973): Contraception with a long acting injectable progestogen "Depo Provera". *Med. J. Cairo Univest.*, 41:215-222.
- 243- Sadler W., Bialy G., Berendes H., and Combs J. (1979): Ten-year report from the center for population research national institute of child health and human development. *Contraception*, 19:335-371.
- 244- Sammour M.B. (1970): The effect of long-acting progestogen-estrogen com

- bination contraception on the vaginal epithelium. In: "Studies on IUDs and Injectables in Arab Republic of Egypt". edited by Osman, E. (1972). Scientific Book Center, Cairo, p.56.
- 245- Sammour M.B., and Abdel Hafiz (1970): The remote changes in the endometrial histology and the cervicovaginal cytology with the long-acting hormonal contraceptives. In: "Studies on IUDs and Injectable in Arab Republic of Egypt". edited by Osman, E. (1972), Scientific Book Center, Cairo. p.57.
- 246- Sammour M.B., and Ibrahim W.N. (1970): A study of the effect of a long acting progestogen-estrogen injectable contraceptive on the liver functions. In: "Studies on IUDs and Injectables in Arab Republic of Egypt". edited by Osman, E., (1972), Scientific Book Center, Cairo. p.58.
- 247- Sanchez F.A., Faundes A., Brache V., and Leon P. (1977): Attainment and maintenance of azospermia with combined monthly injections of Depo medroxyprogesterone acetate and testosterone enanthate. *Contraception*, 15:635-642.
- 248- Scheinberg I.H. (1976): The effects of heredity and environment on copper metabolism. *Med. Clin. Nor. Amer.*, 60:703-712.
- 249- Schenker J.G., Jungreis E., and Polishuk W.Z. (1971): Oral contraceptives and serum copper concentration. *Obstet. Gynecol.*, 37:233-237.
- 250- Schiff I., Tulchinsky D., Cramer D., and Rayan K.J. (1980): Oral medroxy progesterone in the treatment of postmenopausal symptoms. *JAMA*, 244:1443-1445.
- 251- Schroeder H.A., Nason A.P., Tipton I.H., and Balassa J.J. (1966): Essential trace metals in man: copper. *J. Chron. Dis.*, 19:1007-1034.
- 252- Schwallie P.C. (1981): The effect of DMPA on the fetus and nursing infant. *Contraception*, 23:375-386.
- 253- Schwallie P.C., and Assenzo J.R. (1973): Contraceptive use-efficacy study utilizing MPA administered as an intramuscular injection once every 90 days. *Fertil. Steril.*, 24:331-339.
- 254- Sgommeagna A., Lee A.W., and Borushek S. (1970): Evaluation of an injectable progestin-estrogen as a contraceptive. *Am. J. Obstet. Gynecol.*,

- 107:1147-1155.
- 255- Shaaban M.M., Fathalla M., Hammouda A.A., Morad M.M., Sabry A.S., and EL-Khali G.Y. (1972): Experience with once-a-cycle injectable contraceptive. In: "Studies on IUDs and Injectables in Arab Republic of Egypt", edited by Osman, E., Scientific Book Center, Cairo, p.48.
- 256- Shearman R.P. (1975): The development of depot contraceptives. J. Steroid. Biochem., 6:899-902.
- 257- Shroeder H. (1965): The biological trace elements. J. Chron. Dis., 18:217.
- 258- Simpson J.L. (1983): Injectable and implantable progestins: probable lack of fetal effect. In: "Long-Acting Contraception". edited by Goldsmith A., and Toppozada M. Ruvenia Thomas, PARER, Northwestern University, p.52-68.
- 259- Simpson J.L. (1985): Relationship between congenital anomalies and contraception (Abst.), Excerpt. Med. Obstet. Gynaecol., 48:508.
- 260- Simpson G.R., and Dale E. (1972): Serum levels of phosphorus, magnesium, and calcium in women utilizing combination oral or long acting injectable progestational contraceptives. Fertil. Steril., 23:326-330.
- 261- Singh E.J. (1975): Effect of oral contraceptives and IUDs on the copper in human cervical mucus. Obstet. Gynecol., 45:328-330.
- 262- Siritwongse T., Snidvongs W., Tantayaporn P., and Leepipatpaiboon S. (1982): Effect of depo medroxyprogesterone acetate on serum progesterone levels when administered on various cycle days. Contraception, 26:487-493.
- 263- Smith B., and Simpson R.D. (1984): Anorexia, depression and zinc deficiency. Lancet, 2:1162.
- 264- Smith R.P., and Sizto R. (1983): Metabolic effects of two triphasic formulations containing ethinyl oestradiol and dl-norgestrel. Contraception, 28:189-199.
- 265- Soltan M.H., and Jenkins D.M. (1982): Maternal and fetal plasma zinc concentration and fetal abnormality. Br. J. Obstet. Gynaecol., 89:56-58.
- 266- Stadel B.V. (1981): Oral contraceptives and cardiovascular disease. N. Engl. J. Med., 305:612-677.

- 267- Sunderman F.W., and Carroll J.E. (1965): Measurements of serum calcium and magnesium by atomic absorption spectrophotometry. *Am. J. Clin. Path.*, 43: 302-310.
- 268- Svanborg A., and Vikrot O. (1966): The effect of estradiol and progesterone on plasma lipids in oophorectomized women. *Acta Med. Scan.*, 179: 615-621.
- 269- Tepperman J.A. (1973): "Metabolic and Endocrine Physiology". 3rd ed., Year Book Medical Publishers Incorporation, Chicago, p.225-238.
- 270- Thin C.G. (1971): Quoted by Margen S., and King J.C. (1975): Effect of oral contraceptive agents on the metabolism of some trace minerals. *Am. J. Clin. Nutr.*, 28:392.
- 271- Tillott S.M. (1982): Depo-Provera: pregnancies and side effects. *Contracept. Deliv. Syst.*, 3:105.
- 272- Tonelli (1970): Quoted by Upjohn Company (1980): Commentary on Depo-Provera. Kalamazoo, Michigan, USA, p.12-17.
- 273- Toppozada M. (1982): Injectable contraceptives, *Contracept. Deliv. Syst.*, 3:161-170.
- 274- Toppazada M., Nayel S., EL-Sokkary H., and Tork M. (1982): Management of amenorrhoea due to contraceptive injectables by temporary IUD insertion. *Contracept. Deliv. Syst.*, 3:127-133.
- 275- Toppozada M., Parmar C., and Fatherby K. (1978): Effect of injectable contraceptives Depo-Provera and Norethisterone enanthate on pituitary-gonadotropin response to lutenizing hormone-releasing hormone. *Fertil. Steril.*, 30:545-548.
- 276- Tseng L., and Gurpid E. (1975): Effect of progestins on stradiol receptors level in human endometrium. *J. Clin. Endocrinol. Metab.*, 41:402-404.
- 277- Turkington V.E., Nixon J.C., Campbell J.S., and Hurteau G.D. (1971): Effect of long acting steroid contraceptive (MPA) on human female subjects. *Clin. Chem.*, 17:667-672.
- 278- Tuttle S., and Turkington V.E. (1974): Effects of medroxyprogesterone acetate on carbohydrate metabolism. *Obstet. Gynecol.*, 43:685-692.
- 279- Tyler E.T. (1968): Current studies in contraception, the use of a long

- acting progestogen by injection. S. Afr. Med. J., 42:257-259.
- 280- Tyler E.T., Levin M., Elliot J., and Dolman H. (1970): Present status of injectable contraceptives: result of seven years study. Fertil. Steril, 21:469-481.
- 281- Tyler L. (1984): Nutrition and the pill. J. Reprod. Med., 29:547-550.
- 282- Ulmer D.D. (1977): Current concepts-trace elements. N. Engl. J. Med., 297:318-321.
- 283- Underwood E.J. (1977): "Trace Elements in Human and Animal Nutrition". 4th ed., Academic Press, New York, p. 57-361.
- 284- United States Agency for International Development "USAID" (1980): Report to USAID of the AdHoc Consultative Panel on depo medroxyprogesterone acetate. Product information memo, UNFPA piact, 15:6.
- 285- Upjohn Company data: "Depo Provera. 150", Kalamazoo, Michigan USA p.1-20.
- 286- Upjohn Company (1980): Commentary on Depo-Provera. Kalamazoo, Michigan, USA, p. 3-72.
- 287- Upjohn Company (1986): Depo-Provera-issue discussion paper. Kalamazoo, Michigan, USA, p.1-26.
- 288- Utter M.F. (1976): Biochemistry of manganese. Med. Clin. Nor. Amer., 60: 713-727.
- 289- Vallee B.L., Wacker W.E.G., and Ulmer D.D. (1960): The magnesium-deficiency tetany syndrome in man. N. Engl. J. Med., 262:155-161.
- 290- Vallee et al. (1956 and 1957): Quoted by: Burch R.E., and Sullivan, J.F. (1976): Clinical and nutritional aspects of zinc deficiency and excess. Med. Clin. Nor. Amer., 60:675-685.
- 291- Vander A.J., Sherman J.H., and Luciano D.S. (1985): "Human Physiology. The Mechanism of Body Function". 4th ed., Mc Graw-Hill Book Company, New York, p. 447-460.
- 292- Vecchio T.J. (1976): Long acting injectable contraceptives. Adv. Steroid. Biochem. Pharmacol., 5:1-64.
- 293- Vernon W.B., and Wacker W.E. (1978): Magnesium metabolism. In: "Recent Advances in Clinical Biochemistry". No. 1, edited by Alberti K.M., Churchill Livingstone, Edinburgh and London, p. 39-65.

- 294- Versieck J., Barbier F., Speecke A., and Hoste J. (1974): Normal manganese concentrations in human serum. *Acta Endocrinol.*, 76:783-788.
- 295- Vessey M.P. (1978): Steroid contraception, venous thromboembolism and stroke: data from countries other than USA. In: "Risks, Benefits, and Controversies in Fertility Control". edited by Sciarra J.J., Zatuchni G. I. and Speidel J.J., Harper and Row, Hgerstown, London., p 113-121.
- 296- Wacker W.E.C., and Parisi A.F. (1968): Magnesium and zinc metabolism. *N. Engl. J. med.* 278:658-776.
- 297- Webb J.L. (1980): Nutritional effects of oral contraceptive use. *J. Reprod. Med.*, 25:150-155.
- 298- Weiss N., and Sayvetz T. A. (1980): Incidence of endometrial cancer in relation to the use of oral contraceptives. *N. Engl. J. Med.*, 302:551-554.
- 299- West C.P. (1983): The acceptability of a progestogen only contraceptive during breast feeding. *Contraception*, 27:563-569.
- 300- Whigham K.A.E., Howie P.W., Mack A., and Prentice C.R.M. (1979): The effect of an injectable progestogen contraceptive on blood coagulation and fibrinolysis. *Br. J. Obstet. Gynaecol.*, 86:806-809.
- 301- White A., Handler P., and Smith E.L. (1979): "Biochemistry". 5th ed., McGraw-Hill Book Company, New York, p. 1067-1071.
- 302- William S.R. (1981): "Nutrition and Diet Therapy". 4th ed. The C.V. Mosby Company, St. Louis, London, p. 132-165.
- 303- Wilson J.G., and Brent R.L. (1981): Are female sex hormones teratogenic? *Am. J. Obstet. Gynecol.*, 141:567-579.
- 304- Wilson E.S.B., Cruickshank J., McMaster M., and Weir R.J. (1984): A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen. *Br. J. Obstet. Gynecol.*, 91:1254-1260.
- 305- Wootton I.D.P. (1974): "Microanalysis in Medical Biochemistry". 5th ed., Churchill Livingstone, Edinburgh and London, p. 67-71.
- 306- World Health Organization "WHO" (1977): Expanded Programme of Research, Development and Research Training in Human Reproduction: Task force on

long-acting systemic agents for the regulation of fertility. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids; Norethisterone enanthate and Medroxyprogesterone acetate: 1- Use effectiveness. *Contraception*, 15:513-530.

- 307- World Health Organization "WHO" (1977): Safety and efficacy of injectable contraceptives. Press Release-WHO: 25-26.
- 308- World Health Organization "WHO" (1978): Special Programme of Research, Development and Research Training in Human Reproduction: Multinational comparative clinical trial of two long-acting injectable contraceptives steroids: Norethisterone enanthate and Medroxyprogesterone acetate. 2. Bleeding patterns and side effects. *Contraception*, 17:395-409.
- 309- World Health Organization "WHO" (1978): Special Programme of Research, Development and Research Training in Human Reproduction: Safety of the long acting injectable contraceptive. Depo-Provera. p. 1-7.
- 310- World Health Organization "WHO" (1982): Special programme of Research, Development and Research Training in Human Reproduction: "Facts about injectable contraceptives. Bulletin of WHO, 60:199-210.
- 311- World Health Organization "WHO" (1982): Injectable hormonal contraceptives. Technical and Safety Aspects - Geneva - WHO offset publication No. 65:21-45.
- 312- World Health Organization "WHO" (1982): Special Programme of Research, Development and Research Training in Human Reproduction: Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone enanthate and Depot-medroxyprogesterone acetate. A preliminary report. *Contraception*, 25:1-11.
- 313- World Health Organization "WHO" (1983): Special Programme of Research, Development and Research Training in Human Reproduction: Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone enanthate given in two dosage regimens, and Depot Medroxyprogesterone acetate. Final report. *Contraception*, 28:1-21.
- 314- World Health Organization "WHO" (1984): Breast cancer, cervical cancer, and Depot Medroxyprogesterone Acetate. *Lancet*, 2:1207-1208.

- 315- Yassin S., EL-Mahgoub S., Ammar R., and Karim M. (1971): Ovarian morphological changes with injectable contraceptives and their relation cycle control. In: "Studies on IUDs and Injectables in Arab Republic of Egypt " edited by Osman, E. (1972). Scientific Book Center, Cairo, p. 56.
- 316- Younis M.N., Salem H.I., Hamed A.F., EL-Hemaly A.K., EL-Masry G.I. Awad A.H., and EL-Agazy H. (1985): The menstrual pattern and side effects of Depo Medroxyprogesterone Acetate as a postpartum contraceptive. J. Int. Islamic Center for Population Studies and Research. Al-Azhar University. Cairo, 6:97-103.
- 317- Zacharias S., Aguilera E., Assenzo J.R., and Zanartu J. (1986): Effects of Hormonal and non-Hormonal contraceptives on lactation and incidence of pregnancy. Contraception, 33:203-213.
- 318- Zanartu J., Dabancens A., Oberti C., Rogelio R.B. and Garcia H.M. (1974): Low-dosage oral progestogens to control fertility . Obstet. Gynecol., 43: 87-96.
- 319- Zanartu J., and Onetto E. (1972): Quoted by Vecchio T.J. (1976): Long-acting injectable contraceptives. Adv. Steroid. Biochem. Pharmacol., 5:1-46.
- 320- Zilya A., and Pannall F. (1971): Calcium, phosphate and magnesium metabolism. In: "Clinical Chemistry in Diagnosis and Treatment". Lloyd-Luke Book, New York, p. 234-259.
- 321- Zimmerman A.W., Holden K.R., Reiter E.O., and Dekaban A.S. (1973): Medroxyprogesterone acetate in the treatment of seizures associated with menstruation. J. Pediat., 83:959-963.